Most pharmaceutical companies spend months preparing for an FDA inspection. SOPs reviewed. Batch records organized. Staff trained.
And then an Investigator walks in unannounced on a Tuesday morning and the first thing they notice has nothing to do with any of it.
I spent 14 years as an FDA Investigator. I have walked into hundreds of facilities. I know exactly what happens in the first 30 minutes of an inspection — and I can tell you that what happens in those first 30 minutes shapes everything that follows.
FDA inspections are not won or lost during the inspection itself. They are won or lost in the decisions your team makes before an Investigator ever arrives, and in the critical hours after they leave.
What Most Companies Get Wrong
The standard inspection preparation advice is not wrong. It is just incomplete.
Document control, SOP currency, CAPA closure rates — these are the baseline. Every company that gets a Warning Letter had SOPs. Every company that receives an OAI classification had trained staff. Procedures on paper do not determine inspection outcomes. Execution under pressure does.
The companies that navigate FDA inspections successfully understand something that most compliance training programs never teach: FDA Investigators are evaluating your quality culture from the moment they badge in. They are drawing conclusions about organizational control, management commitment, and system reliability before a single document is requested.
By the time your most senior quality leader sits down across from the Investigator, a preliminary picture has already been formed.
The First 30 Minutes Matter More Than You Think
An unannounced inspection gives you no time to prepare in the moment. What you can control is how your team responds when it happens.
How long the Investigator waits at reception. Who greets them and who is suddenly unavailable. Whether your opening meeting is structured and confident or improvised and reactive. Whether your document retrieval is smooth or visibly scrambled.
None of these things appear on a 483. All of them influence how an Investigator characterizes what they find.
The gap between a routine inspection and a for-cause inspection is often not the severity of the deficiencies. It is the confidence an Investigator develops — or loses — in your organization’s ability to control its own systems.
What Happens After the Investigator Leaves
The inspection does not end when the Investigator walks out the door. What your team does in the hours and days that follow, how you respond to observations, how you engage with the district office, how you manage the classification process has a direct impact on whether your inspection results in routine follow-up or regulatory escalation.
Most companies treat the post-inspection period as a waiting game. Experienced companies treat it as the most important phase of the entire inspection cycle.
The Five Strategies
There are five specific insider strategies — drawn from 14 years of FDA field experience and 13 years on the industry side — that address every phase of the inspection cycle: the first 30 minutes, document management, 483 interpretation, closeout meeting intelligence, and post-inspection classification influence.
None of them are in your SOP manual. None of them are taught in standard GMP training. They reflect how FDA’s inspection system actually operates — from the inside.
They are in The Investigator’s Lens.
Read the full article here: https://devaughnedwards.substack.com/p/five-fda-insider-tips-for-handling?r=7sflcx
DeVaughn Edwards is a former FDA Investigator with 14 years of field experience, a pharmaceutical quality executive with 13 years of hands-on compliance leadership, and the founder of FD-AID LLC. He conducts mock FDA inspections and inspection readiness engagements for pharmaceutical manufacturers, CDMOs, and biologics facilities.
Contact: devaughn@fdaid.org | fdaid.org | 732-895-7831
FD-AID | FDA Inspection Readiness | Former FDA Investigator 